Provention Bio, Inc. (PRVB): Price and Financial Metrics


Provention Bio, Inc. (PRVB)

Today's Latest Price: $14.53 USD

0.69 (-4.53%)

Updated Jan 25 6:55pm

Add PRVB to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

PRVB Stock Price Chart Interactive Chart >

Price chart for PRVB

PRVB Price/Volume Stats

Current price $14.53 52-week high $20.05
Prev. close $15.22 52-week low $4.72
Day low $13.91 Volume 1,699,400
Day high $15.30 Avg. volume 1,554,407
50-day MA $16.38 Dividend yield N/A
200-day MA $13.80 Market Cap 820.77M

Provention Bio, Inc. (PRVB) Company Bio

Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.

Most Popular Stories View All

• Is General Motors the Next Tesla?

• How to Outperform the Stock Market in 2021

• 2 Chinese Stocks Rated Strong Buy: EHang and Daqo

• 3 Lesser-Known Cloud Stocks to Add to Your Portfolio

• Is Virgin Galactic a Buy After a New Space Stock ETF was announced?

View All Top Stories

PRVB Latest News Stream

Event/Time News Detail
Loading, please wait...
View All PRVB News

PRVB Latest Social Stream

Loading social stream, please wait...

View Full PRVB Social Stream

Latest PRVB News From Around the Web

Below are the latest news stories about Provention Bio Inc that investors may wish to consider to help them evaluate PRVB as an investment opportunity.

Provention Bio Prices Public Offering at $16 Per Share; Shares Drop 14%

Provention Bio, Inc. declared that the previously announced public offering of 6.25 million shares will be priced at $16 per share. Shares of the biopharmaceutical company dropped 14% yesterday to close at $16.66. Gross proceeds from the offering are expected to be $100 million and the underwriters of the offering have been offered a 30-day call option on an additional 937,500 shares. The offering is expected to close around January 19, 2021. Provention Bio (PRVB) focuses on developing therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases, including celiac and lupus. Proceeds from the public offering will be used for general corporate purposes and the development therapies.

Daniel Plaks on TipRanks | January 14, 2021

Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its…

PR Newswire | January 13, 2021

Provention Bio Announces Proposed Public Offering of Common Stock

RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock….

PR Newswire | January 12, 2021

Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

Yahoo | January 12, 2021

Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market

Provention Bio (PRVB) is focused on preventing, or at least slowing the onset of, type 1 diabetes (T1D) and other autoimmune conditions. This is an important, unmet need because most therapies are focused on treatment after diagnosis and are something that a patient typically has to take for the rest...

Andy Jones on Seeking Alpha | January 7, 2021

Read More 'PRVB' Stories Here

PRVB Price Returns

1-mo N/A
3-mo 23.24%
6-mo 37.20%
1-year -9.36%
3-year N/A
5-year N/A
YTD -14.23%
2020 13.69%
2019 741.81%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.913 seconds.